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Phosphodiesterase (PDE) 4 inhibitors have been shown to
induce the cAMP-mediated signaling pathway by inhibiting
cAMP hydrolysis. This study investigated the effect of a PDE4
inhibitor on the expression of the inducible cAMP early
repressor (ICER), which is an endogenous inhibitor of CRE-
mediated transcription, in osteoblastic cells. RT-PCR analysis
revealed that rolipram, a PDE4 inhibitor, stimulates the ICER
mRNA in a dose dependent manner. The induction of ICER
mRNA expression by rolipram was suppressed by the inhibi-
tors of protein kinase A (PKA) and p38 MAPK, suggesting
the involvement of PKA and p38 MAPK activation in ICER
expression by rolipram. It was previously shown that rolipram
induced the expression of TNF-related activation-induced
cytokine (TRANCE, also known as RANKL, ODF, or OPGL)
in osteoblasts. This paper provides evidences that a transcrip-
tional repressor like ICER might modulate TRANCE mRNA
expression by rolipram in osteoblasts.
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INTRODUCTION
Osteoporosis and other diseases involving bone
loss are a major public health problem. Despite
the recent successes with drugs that inhibit bone
resorption, notably bisphosphonates, there is a
clear therapeutic need for bone anabolic mole-
cules, particularly in patients who have already
suffered substantial bone loss.
Parathyroid hormone (PTH) and prostaglandin
E2 (PGE2) stimulate bone formation in experimen-
tal animals and humans.
1-3 Several studies suggest
that cyclic AMP (cAMP), which initiates protein
kinase A (PKA) signaling, mediates the anabolic
effects of these two molecules.
3,4 Many cAMP-res-
ponsive genes have been identified in PTH-treated
osteoblasts, including collagenase,
5 c-fos,
6 type I
collagen,
7 interleukin-6,
8 cycloxygenase-2 (cox-2),
9
TNF-related activation-induced cytokine (TRANCE,
also known as RANKL, ODF, or OPGL),
10 and
inducible cAMP early repressor (ICER).
11
ICER is a member of the cAMP response ele-
ment binding protein (CREB) and CRE modulator
(CREM) family of transcription factors, which
bind to CREs.
12 The ICER is generated in an in-
ducible manner when an internal promoter of the
CREM gene, containing CRE sites, is stimulated
by increased cAMP levels.
12 Because the ICER
consists of only a DNA-binding domain identical
to the one in the CREM and lacks the transac-
tivation domain, the ICER serves as a dominant-
negative of CREM/CREB-mediated transcrip-
tion.
12
Intracellular cAMP is generated by adenylate
cyclase from adenosine triphosphate (ATP) as a
substrate, whereas cAMP-specific phosphodie-
sterases (PDEs) catalyze the hydrolysis of cAMP
to 5'-AMP.
13,14 Therefore, the intracellular cAMP
gradients are governed by a balance between its
generation by adenylate cyclase and degradation
by the PDEs.
The PDE family consists of 11 isozymes ranging
from PDE1 to 11. Those isozymes involved in the
degradation of cAMP are PDE1, 2, 3, 4, 7, 8, 10,
and 11, with some of these PDE isozymes being
further classified into subtypes.
14 Rolipram, a
PDE4 specific inhibitor, has recently been demon-
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strated to increase the bone mass mainly by pro-
moting bone formation in normal mice.
15 Fur-
thermore, PDE4 inhibitors have been shown to
have therapeutic effects in different experimental
osteopenia models.
16,17 Although it has been
hypothesized that PDE4 inhibitors can mimic the
anabolic effects of PTH and PGE2 on the bone,
little is known about the precise mechanism by
which the PDE4 inhibitors regulate the expression
of the osteoblastic genes.
In this study, rolipram was shown to induce
ICER mRNA expression in mouse osteoblastic
cells. It was found that rolipram-dependent ICER
mRNA expression was mediated possibly by the
PKA and p38 mitogen-activated protein kinase
(MAPK) pathway, with little contribution from
the extracellular signal-regulated kinase (ERK)
MAPK pathway. It was also suggested that ICER
might play an important modulatory role in the
rolipram-mediated regulation of TRANCE, which
is an essential molecule for osteoclastogenesis,
18-20
in osteoblasts.
MATERIALS AND METHODS
Reagents
H89, PD98059 and SB203580 were obtained from
Calbiochem (San Diego, CA). All other reagents
were purchased from Sigma-Aldrich (St. Louis,
MO).
Cells
Primary calvarial osteoblasts were isolated from
the calvariae of neonatal ddY mice (Japan SLC
Inc., Shizuoka, Japan) by a conventional method
using 0.1% collagenase and 0.2% dispase. UAMS-
32, which is an osteoblastic/stromal cell line, was
a kind gift from Prof. Masamichi Takami (Showa
University, Tokyo, Japan). All the cells were cul-
tured in α-MEM/10% FBS at 37 and 5% CO2.
RT-PCR analysis
Total RNA (1 g) was reverse-transcribed using μ
Superscript II (Invitrogen, CA, USA) according to
the manufacturer's protocols. Aliquots of the
obtained cDNA pool were subjected to PCR
amplification with Go Taq DNA polymerase
(Promega Co., WI, USA). The primers for ICER
and glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) used in this study are as follows: ICER,
5'-gatactggagatgaaactga -3' (forward), 5'-ctttctcatac
agttcacag-3' (reverse); and GAPDH, 5'-gaaggtcgg
tgtgaacggatttggc-3' (forward), 5'-catgtaggccatgaggt
ccaccac-3' (reverse). The PCR program is as
follows: 40 (ICER) or 28 (GAPDH) cycles, after an
initial denaturation step at 94 for 3 minutes,
then denaturation at 94 for 30 seconds, an-
nealing at 48?C (ICER) or 52 (GAPDH) for 45
seconds, and extension at 72 for 60 seconds,
with a final extension at 72 for 10 minutes.
Immunoblot analysis
Total protein extracts were isolated from the
rolipram-treated UAMS-32 cells. After separation
in SDS-PAGE, the proteins were transferred onto
Immobilon-P membranes (Millipore, Bedford,
MA). The membranes were blocked with 5%
nonfat-milk in TBS-T (150 mM NaCl, 20 mM Tris,
pH 7.4, 0.1% Tween 20), and then immunostained
with either the anti-phospho p38 antibody (1:1000)
or the anti-p38 antibody (1:1000) followed by sec-
ondary horseradish peroxidase-conjugated anti-
body (1:5000, Cell Signaling Technology). The
membranes were developed using an enhanced
chemiluminescence detection kit (Amersham
Biosciences, Bukinghamshire, UK).
Northern blot analysis
Cells in 60-mm diameter dishes were cultured
with the agents for the indicated periods, and
subjected to total RNA isolation using Trizol
reagent (Invitrogen, CA, USA) according to the
manufacturer's protocol. The total RNA (20 g) μ
was electrophoresed in 1.2% agarose-formaldehyde
gels, transferred to nylon membrane filters (Hybond
N+, Amersham Biosciences, Bukinghamshire,
UK), and hybridized with the
32P-labeled cDNA
probes. The cDNAs encoding TRANCE and
GAPDH cloned by polymerase chain reaction
(PCR) were used as the probes. After the final
wash, the membrane was exposed to an X-ray
film (BioMax, Kodak, Rochester, NY) at -70 .Effects of PDE4 Inhibitor on ICER Expression 151
Yonsei Med J Vol. 46, No. 1, 2005
RESULTS
Rolipram induces ICER mRNA expression in
osteoblastic cells
The effect of rolipram, a selective PDE4 inhibi-
tor, on ICER mRNA expression was examined
using RT-PCR in osteoblastic cells. Although there
are four isozymes in the ICER family (ICER-I,
ICER-Iγ, ICER-II, and ICER IIγ), the function of
each isoform identified thus far is indistingui-
shable.
12 Rolipram induced mRNA expression of
ICER-I (700 bp) and ICER-II (262 bp) in UAMS-32
cells as early as 1 hr, which persisted for up to
9 hrs (Fig. 1A). In order to determine the dose-
dependence of rolipram-induced ICER mRNA
expression, the UAMS-32 cells were treated with
various concentrations of rolipram for 3 hrs. Fig.
1B shows that 0.01-10 M rolipram stimulated the μ
ICER in a dose-dependent manner. These results
demonstrate that rolipram strongly induces ICER
mRNA expression in osteoblastic cells.
Inhibitors of PKA and p38 MAPK, but not of
ERK, suppress ICER mRNA expression induced
by rolipram
In order to identify the signaling pathways used
by rolipram to induce ICER expression, the roles
of the PKA-, ERK-, and p38 MAPK signaling
cascades in ICER expression were examined. The
cAMP-PKA pathway is essential for PTH-depen-
dent ICER expression in osteoblasts.
21 Consistent
with this, pretreatment of UAMS-32 cells with
H89, a PKA inhibitor, decreased the ICER mRNA
expression levels induced by rolipram (Fig. 2A).
Furthermore, SB203580, a p38 MAPK inhibitor,
also decreased the ICER mRNA expression levels
induced by rolipram. However, a MAPK/ERK
kinase (MEK) inhibitor, PD98059, did not affect
the ICER mRNA levels induced by rolipram (Fig.
2A). Immunoblot analysis with a phospho-p38-
specific antibody confirmed that rolipram stimu-
lates the rapid phosphorylation of p38 with its
maximum effect at 15 min (Fig. 2B). This suggests
that rolipram regulates ICER mRNA expression in
osteoblastic cells possibly via the activation of the
PKA and p38 MAPK signaling pathways, but not
via the activation of the ERK MAPK pathway.
ICER may play an important modulatory role in
attenuating TRANCE mRNA expression in
osteoblasts
It was previously reported that rolipram
stimulates TRANCE mRNA expression in osteo-
blastic cells.
22 In order to determine if interme-
diate gene expression is essential for the effects of
rolipram on TRANCE expression, the UAMS-32
cells were treated with rolipram for 3, 9, 24 hrs
in the presence or absence of the protein synthesis
inhibitor, cycloheximide. Cycloheximide alone
stimulated the TRANCE mRNA levels at 3 and 9
hrs but did not block the additional stimulatory
action of rolipram in the UAMS-32 cells (Fig. 3A).
This indicates that rolipram stimulates TRANCE
Fig. 1. Effect of rolipram, a PDE4 inhibitor,
on ICER mRNA expression in UAMS-32
cells. A. The cells were treated with 5 M μ
rolipram for the indicated times, or B. with
the indicated concentrations of rolipram for
3 hrs. The total RNA was prepared and
reverse transcribed in the presence (+RT) or
absence (-RT) of reverse transcriptase, and
the cDNA was amplified using specific
primers designed for the genes of ICER-I
(700 bp) and -II (262 bp). M=0.1 kb DNA
marker.
A
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mRNA expression in osteoblastic cells directly.
The expression level of TRANCE mRNA by
rolipram decreased at 9 hrs and returned almost
to the baseline by 24 hrs (Fig. 3A). However,
pretreatment of cycloheximide caused a con-
tinuing increase in the TRANCE mRNA expres-
sion level at 9 hrs, suggesting the possible in-
volvement of a transcriptional repressor such as
ICER on TRANCE expression in osteoblastic cells.
Primary mouse calvarial cells were used in order
to exclude the possibility that the effect of
cycloheximide on rolipram-induced TRANCE
expression is unique in UAMS-32 cells. As shown
in Fig. 3B, similar results were also obtained in
primary mouse calvarial cells.
DISCUSSION
This study showd that rolipram, a PDE4 inhibi-
tor, rapidly induces ICER mRNA in UAMS-32
osteoblastic cells (Fig. 1). A similar induction of
ICER mRNA by cAMP was reported in other cells
and tissues including pituitary corticotrophs,
23
PC12 cells,
12 mouse calvaria
11 and rat thyroid
gland.
24 The stimulation of the PKA pathway has
been suggested to be a mediator of cAMP-induced
ICER mRNA expression in many experimental
models.
12,24,25 In agreement with this, rolipram was
found to induce ICER mRNA expression in
osteoblastic cells via the PKA signaling pathway
(Fig. 2A).
Interestingly, nerve growth factor (NGF) was
demonstrated to induce ICER in adrenal PC12
cells via the ras-MAP kinase pathway.
26 It was
shown that the activation of p38 MAPK, as well
as PKA, possibly mediates ICER mRNA induction
by rolipram in osteoblastic cells (Fig. 2). These
results suggest that ICER expression may not be
exclusively coupled to the cAMP-PKA pathway.
ICER is believed to be a repressor of cAMP-
induced transcription. For example, in the pineal
gland ICER has been reported to be involved in
the repression of melatonin synthesis during the
course of the normal circadian rhythm.
25 ICER
inhibits the PKA-stimulated transcriptional ac-
tivity of tyrosine hydroxylase in PC12 cells.
27 ICER
has also been shown to play a regulatory role in
Fig. 2. The involvement of signal transduction pathways in
ICER mRNA expression by rolipram. A. The UAMS-32
cells were preincubated in the presence or absence of 30μ
M of H89, 50 M of PD98059, or 50 μ M of SB203580 μ
(inhibitors of PKA, ERK, and p38 MAPK, respectively) for
30 min, and then treated with 5 M rolipram for 3 hrs. μ
Total RNA was extracted from the cells and the expression
of the ICER was examined by RT-PCR analysis. M=0.1kb
DNA marker. B. The UAMS-32 cells were incubated with
5 M rolipram for the indicated times. The total cellular μ
protein was analyzed by immunoblotting with the
antibodies for phospho-p38 after which the membranes
was stripped and incubated with the anti-p38 antibodies.
Fig. 3. The attenuation of rolipram-induced TRANCE
mRNA expression requires the transcriptional repressor in
osteoblasts. A. UAMS-32 cells were treated with 5 μM
rolipram, 1 μg/ml cycloheximide (CHX) or rolipram and
CHX (the CHX was added 1hr before the rolipram). The
total RNA was extracted from the cells at the indicated
times. Total RNA was analyzed by Northern blot using
probes for TRANCE and GAPDH. B. primary mouse
calvarial cells were treated in a similar manner shown in
A.
A
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PTH-stimulated COX-2 transcription in osteo-
blastic cells.
9 The mechanism by which ICER
inhibits the cAMP-inducible genes typically in-
cludes binding to a variety of cAMP response
elements (CREs) or CRE-like sequences in the pro-
moters of target genes that are binding sites for
the activator forms of the CRE-binding protein
(CREB) and/or the related factors of the CREM.
12
Because the ICER lacks the CREM transactivation
domain,
12 which is similar in sequence to that of
CREB, the binding of ICER to a CRE does not
allow the recruitment of either CREB or the
CREB-binding protein (CBP/p300) to activate
transcription.
The activation of the cAMP-PKA pathway in-
duces the expression of TRANCE in osteoblasts,
which triggers osteoclast differentiation.
28,29 Re-
cently, cAMP-stimulated TRANCE expression was
demonstrated to involve CREB-mediated tran-
scription.
30 The attenuation of rolipram-induced
TRANCE mRNA expression was shown to require
the de novo protein synthesis in osteoblasts (Fig.
3), suggesting the possible role of a repressor
protein such as ICER. It has been suggested that
the rapid activation of ICER could serve as a
protective mechanism by which the cell limits
mRNA accumulation of the CRE-containing
genes, and that this regulation subverts the patho-
logical consequences of the chronic stimulation of
activation of PKA.
23 Therefore, the enhanced
expression of TRANCE by the activation of PKA
would be determined by a complex balance of
activation by CREB and repression by ICER,
providing a system for the fine modulation of
gene expression. Although no direct evidence on
the functional ability of ICER to negatively
regulate TRANCE mRNA expression is currently
available, it is likely that future studies will reveal
the additional roles of the ICER in the down-
regulation of TRANCE mRNA expression.
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